PracticeUpdate: Conference Series | ADC 2018

3 reasons to choose JANUVIA as your DPP4-i of choice in T2DM

JANUVIA : Strong HbA1c reductions when added to metformin 2


-1.1% HbA1c reductions

† with JANUVIA (n=82) from a baseline HbA1c of ≥8-<9% at week 52 vs -1.1% for glipizide (n=82) when added to metformin (subgroup of primary endpoint) 2

Uncontrolled on metformin 2

JANUVIA : Consistent HbA1c reductions in any stage of renal impairment 1,-3,6 (with dose adjustment where eGFR <50ml/min/1.73m 2 ) 1,3,4


Normal to mild renal impairment 2 n=382) at 52weeks vs.glipizide: -0.7% (mean baseline 7.5%; n=411) -0.7%

Moderate to severe renal impairment 6#

End - StageRenal Disease (ESRD) on Dialysis 3# n=64) at 54 weeks vs. glipizide:^ -0.9% (mean baseline 7.8%; n=65) -0.7% LS† mean HbA1creduction from baseline (mean 7.9%;


LS†meanHbA1c reduction frombaseline (mean 7.5%;

mean HbA1c reduction from baseline (mean 7.6%; n=33)

at 54 weeks vs. placebo/glipizide:^ -1.0% (mean baseline 7.8%; n=16)

^Glipizide is contraindicated in severe renal insufficiency 7 # Moderate renal insufficiency: CrCl ≥ 30 to < 50mL/min; 6 severe renal insufficiency: CrCl < 30mL/min 3 †LS=least squares

JANUVIA : Demonstrated CV safety profile in the TECOS CV Safety Trial in T2DM patients with established CVD 5 when added to usual care * (median 3 years follow up) 5*


JANUVIA met the primary endpoint:

JANUVIA met all secondary CV safety endpoints:

Non-inferior to placebo for composite cardiovascular related death, nonfatal MI, nonfatal stroke or unstable angina requiring hospitalisation (n=14,671). 5

Including no increased risk of hospitalisation for heart failure vs. the placebo group. 5

* Usual care consisted of open label antihyperglycaemic agents as required during the study, with the aimof achieving individually appropriate HbA1c targets in all patients. Study designs provided in primary advertisement in this publication. CV=cardiovascular, CVD=cardiovascular disease, eGFR=estimated glomerular filtration rate, LS = least squares, MI =myocardial infarction Before prescribing please review the PBS and Product Information in the primary advertisement in this publication. References: 1. JANUVIA Approved Product Information, April 2017. 2. Nauck MA et al. Diabetes Obes Metab 2007;9(2):194–205. 3. Arjona Ferreira JC et al. Am J Kidney Dis 2013;61(4): 579-587. 4. Arjona Ferreira JC et al. Diabetes Care 2013;36(5): 1067-1073. 5. Green JB et al. N Engl J Med 2015; 373(3): 232–242. 6. Chan JCN et al. Diabetes Obes Metab 2008;10:545–555. 7. Melizide (glipizide) Approved Product Information, October 2015.

Copyright © 2018 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey, U.S.A. All rights reserved. Merck Sharp & Dohme (Australia) Pty Limited. Level 1, Building A, 26 Talavera Road, Macquarie Park NSW 2113. DIAB-1268045-0000. First Issued August 2018. Bloe Agency MSD13139.

Made with FlippingBook - Online Brochure Maker